Dear Sir, Induced hypertension due to treatments with recombinant erythropoietin (rHuEPO) is with no doubt the most frequent and important side effect of this hormone therapy, capable of conditioning the therapeutic success in subjects affected by anemia from renal failure. Although different factors, among which the increase in hematic viscosity, are recognized as possibly responsible for the pressure rise which often goes along with rHuEPO treatment, up to now a reliable explanation of the pathogenetic mechanisms of hypertension induced by erythropoietin [1] is still missing. In previous investigations, through the evaluation of the changes brought about by the intravenous administration of rHuEPO on the pretibial flux by means of the Xenon 133 clearance, we showed the existence of a direct vasoconstric-tive action exerted by erythropoietin on the compliance vasa [2]. The presence of endothe-lial receptors for the erythropoietin could give account of such action [3]. Furthermore, in our previous investigations as well as in other investigations [4], it was shown how the intravenous chronic treatment was able to change the plasma levels of endothel·in-1, a substance produced by the endothelium, able to induce a high vasoconstriction. Yet, the plasma dosage of endothelin does not seem to correspond to the real activity of the vasal endothelium. Therefore, we wanted to use an experimental model based on the umbilical arteries, where the receptors for endothelin are to be found [5]. The arteries were quickly Fig. 1 . Production of immunoreactive endothelin-1 (ir ET-1) in the umbilical artery: electrolytic solution (I); rHuEPO solvent (II); 30 U of rHuEPO (III). 20 µl of solvent. Then, the 3 umbilical artery segments were kept for 10 min at 37 °C, were weighed and the corresponding supernatant frozen at -30 °C, the endothelin-1 was dosed with the RIA method (Amersham, UK). The results obtained from 25 umbilical arteries showed the presence of a significant increase in the concentration of endothelin-1 from the medium to
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